MedTrace Logo

Linezolid-resistant Staphylococcus Epidermidis in ICU and Risk Factors Analysis

NCT03140410 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2017-09-12

No results posted yet for this study

Summary

Understanding the emergence of linezolid-resistance in Staphylococci has been allowed in the past years through the discovery of the clonal dissemination of a chromosomal cassette carrying a modified crf gene. New mutations have even been described. Though, clinical evidences are still lacking, especially concerning the factors associated to this emergence. It could seriously become quite problematic to eliminate one of the last therapeutic weapon at our disposal for the treatment of severe or complicated infections caused by resistant strains of Staphylococci and Enterococci.

We aim to describe the mechanisms that permitted to this resistance to become clinically significant, concerning meticillin-resistant Staphyloccocus epidermidis strains causing blood stream infections in ICU patients, and show the clinical risk factors associated with it through a case-control study on patients hospitalized in two ICUs of our hospital between 2011 and 2016.

Conditions

  • Health Care Associated Infection
  • Antibiotic Resistant Strain
  • Infection Transmission

Interventions

OTHER

Antibiotic resistance

Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group. Screening for the presence of "crf" gene, and mutations associated

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Principal Investigators

  • Xavier Bertrand, MD,PhD · Service d'Hygiène Hospitalière, CHU Jean Minjoz Besançon - Université de Franche-Comté, Faculté de Sciences Médicales et Pharmaceutiques

  • Catherine Chirouze, MD,PhD · Service de Maladies Infectieuses et Tropicales, CHU Jean Minjoz Besançon - Université de Franche-Comté, Faculté de Sciences Médicales et Pharmaceutiques

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-28
Primary Completion
2017-10-20
Completion
2018-01-02

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03140410 on ClinicalTrials.gov